Manager TitleAgeSince
Chief Executive Officer - 2018-04-01
Director of Finance/CFO - 2017-11-06
Chief Tech/Sci/R&D Officer - 2016-02-29
Director TitleAgeSince
Chairman 72 2016-02-29
Director/Board Member - 2016-02-29
Director/Board Member - 2016-02-29
Date Insider Type Main position Quantity % Market Cap. Importance
6/3/26 Marche

Chairman

-116,227 0.6244%
6/3/26 Marche

Director

-58,500 0.3143%
6/3/26 Marche

Director

-30,188 0.1622%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+5.33% - - 10.56M
-0.61%+0.91%+4.55%+7.54% 369B
-1.50%+4.42%+14.36%+8.48% 255B
-2.05%-0.58%-8.02%+11.48% 140B
-0.52%-1.83%+18.86%+27.72% 73.48B
+0.11%+6.28%+29.60% - 52.06B
-0.12%-1.86%-27.28%-26.84% 44.97B
+0.89%+5.45%+10.68%-12.22% 39.2B
-0.51%+1.52%+33.22%+6.15% 37.32B
-0.64%+1.65%-10.16%-7.24% 36.28B
Average -0.49%+1.71%+7.31%+1.88% 116.41B
Weighted average by Cap. -0.90%+1.71%+6.88%+6.90%
Logo Crescita Therapeutics Inc.
Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment is engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. The Manufacturing and Services segment is engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.
Employees
65